Thomas Jung

About Aimm Therapeutics
Board member Thomas Jung

Board of directors

Thomas Jung, MD, PhD

A translational medicine specialist, Thomas Jung possesses extensive expertise in proof-of-concept studies that span the major disease areas. While with Novartis, Jung led 11 major drug development programs from preclinical studies to marketing authorization including the approval of Ilaris (Canakinumab) for Cryopyrin Associated Periodic Syndromes and three other indications. Presently, Jung serves as chief medical officer at Delenex Therapeutics.